Can Novartis slim down CAR-T manufacturing timelines with its latest acquisition attempt?
Novartis has offered to buy a cell and gene therapy manufacturer in an ongoing effort to unclog a commercial rollout for its pioneering CAR-T therapy Kymriah that’s been slowed down by manufacturing woes.
Set to become a wholly owned Novartis facility, CellforCure first signed an agreement to produce Kymriah in July 2018. With the tech transfer complete, the clinical supply production is expected to begin by mid-2019 — when the deal is expected to close.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.